{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:56:27Z","timestamp":1787504187677,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1195021"],"award-info":[{"award-number":["1195021"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009399","name":"Macular Disease Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n To provide insights into the effectiveness and safety of faricimab for treatment\u2010na\u00efve eyes with neovascular age\u2010related macular degeneration (nAMD).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A retrospective cohort study using a prospectively\u2010designed registry. Treatment\u2010na\u00efve eyes with\n nAMD<\/jats:styled-content>\n in Australia starting treatment with faricimab between Jan 2023\u2013Sep 2024 were included. Controls were treatment\u2010na\u00efve eyes starting with aflibercept 2\u2009mg before 2022. Visual acuity (\n VA<\/jats:styled-content>\n ), macular neovascularisation activity, time to first inactivity, number of injections, injection intervals and number of visits at 12\u2009months were investigated. Eyes treated with faricimab versus aflibercept 2\u2009mg were compared using overlap weighting. The main outcome measure was the 12\u2010month\n VA<\/jats:styled-content>\n change.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Twenty\u2010three practitioners treated 160 eyes with a 4\u2010letter gain in\n VA<\/jats:styled-content>\n (mean, 61.5\u201365.5 letters) and 48% attaining a dosing interval of \u2265\u200912\u2009weeks, although 22% were still treated at <\u20098 weekly intervals. The small proportion (6.9%) of eyes switching to another agent had improved vision but were mostly active when switching off faricimab. Eyes received 7.2 injections (mean) at 7.4 visits (mean), receiving treatment at 98% of visits indicating a strongly proactive treatment regimen. Most (71%) lesions became inactive by 12\u2009months with a mean time to inactivation of 10.3\u2009weeks. Eyes starting faricimab had a significantly higher inactivation rate with more eyes reaching the last injection interval of \u2265\u200912\u2009weeks than those starting aflibercept 2\u2009mg.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n These findings indicate that faricimab is safe and effective for treatment\u2010naive eyes with\n nAMD<\/jats:styled-content>\n . Faricimab had a stronger effect on\n nAMD<\/jats:styled-content>\n lesion activity than aflibercept 2\u2009mg.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ceo.70072","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:20:17Z","timestamp":1770596417000},"page":"500-506","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Twelve\u2010Month Real\u2010World Outcomes of Faricimab for Treatment\u2010Naive Neovascular\n AMD<\/scp>\n in Australia"],"prefix":"10.1111","volume":"54","author":[{"given":"Mark","family":"Gillies","sequence":"first","affiliation":[{"name":"Save Sight Institute, The Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Save Sight Institute, The Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman","family":"Nazari","sequence":"additional","affiliation":[{"name":"The Royal Victorian Eye and Ear Hospital East Melbourne Victoria Australia"},{"name":"Croydon Eye Clinic Croydon Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arnold","sequence":"additional","affiliation":[{"name":"Marsden Eye Specialists Parramatta New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Wang","sequence":"additional","affiliation":[{"name":"Save Sight Institute, The Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barry","sequence":"additional","affiliation":[{"name":"Canberra Health Services Blink Eye & Vision Clinics, University of Canberra, University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Ferrier","sequence":"additional","affiliation":[{"name":"Coastwide Eye Surgery Erina New South Wales Australia"},{"name":"Central Coast Local Health District Gosford New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Game","sequence":"additional","affiliation":[{"name":"Port Macquarie Eye Centre Port Macquarie New South Wales Australia"},{"name":"Mid North Coast Local Area Health Service Port Macquarie New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Hospital Zurich and University of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-00920-3"},{"key":"e_1_2_10_6_1","unstructured":"Institute for Accountable Care \u201cTrends in Medicare ACO Cost and Use of Biologic Therapies to Treat Age\u2010Related Macular Degeneration \u201daccessed June 10 2025 https:\/\/www.institute4ac.org\/wp\u2010content\/uploads\/2023\/12\/IAC_Part\u2010B\u2010AMD\u2010Drugs_White\u2010Paper_Dec\u20102023_FINAL.pdf."},{"key":"e_1_2_10_7_1","unstructured":"The Royal College of Ophthalmologists \u201cNational Ophthalmology Database Audit. The Third Report of Age\u2010Related Macular Degeneration Audit (AMD) \u201d2025 accessed June 10 2025 https:\/\/live\u2010nod\u2010audit.pantheonsite.io\/sites\/default\/files\/2025\u201003\/NOD%20Audit%20Full%20Annual%20Report%202025_Final%20%281%29.pdf."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.07.039"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14141568"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296b271"},{"key":"e_1_2_10_11_1","volume-title":"National Statement on Ethical Conduct in Human Research","author":"National Health and Medical Research Council","year":"2023"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14353"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.01.023"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8533"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280213484401"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199001000-00010"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.012"},{"key":"e_1_2_10_18_1","unstructured":"The Pharmaceutical Benefits Scheme \u201cFARICIMAB [Internet] \u201daccessed December 17 2025 https:\/\/www.pbs.gov.au\/medicine\/item\/14788H\u201014789J\u201014799X\u201014817W\u201014864H\u201014873T."},{"key":"e_1_2_10_19_1","unstructured":"The Pharmaceutical Benefits Scheme \u201cAFLIBERCEPT [Internet] \u201daccessed December 17 https:\/\/www.pbs.gov.au\/medicine\/item\/12132M\u201012141B\u201012152N\u201012153P\u201013139M\u201013141P\u201013150D\u201013167B."}],"container-title":["Clinical & Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.70072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ceo.70072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.70072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:48:30Z","timestamp":1780541310000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.70072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/ceo.70072"],"URL":"https:\/\/doi.org\/10.1111\/ceo.70072","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,8]]},"assertion":[{"value":"2025-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}